\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ physical\\ exam\\ patient\\ has\\ an\\ enlarged\\,\\ nontender\\ thyroid\\ gland\\ without\\ palpable\\ nodules\\.\\ \\ labs\\ were\\ significant\\ for\\ tsh\\ \\<0\\.08\\ \\Â\\µiu\\/ml\\ \\(normal\\ 0\\.5\\-5\\.0\\ \\Â\\µiu\\/ml\\)\\,\\ free\\ t4\\ of\\ 5\\.88\\ \\(normal\\ 0\\.71\\-1\\.85\\)\\,\\ and\\ t3\\ of\\ 510\\.55\\ \\(normal\\ 59\\.00\\-174\\.00\\)\\.\ \(0\)\
\-\ patients\\ was\\ treated\\ with\\ \\ radioiodine\\ ablation\\ using\\ 15\\ mci\\ of\\ \\ i\\-131\\.\ \(0\)\
\-\ thyroid\\ uptake\\ using\\ 7\\Â\\µci\\ of\\ i\\-131\\ and\\ thyroid\\ scan\\ using\\ 10\\ mci\\ tc\\-99m\\.\\ \\ the\\ 24\\ hour\\ radioiodine\\ uptake\\ was\\ determined\\ to\\ be\\ 89\\.4\\%\\ \\(normal\\ range\\,\\ 8\\-30\\%\\)\\.\\ \\ the\\ planar\\ and\\ pinhole\\ scan\\ of\\ the\\ neck\\ shows\\ diffuse\\,\\ homogenous\\ uptake\\,\\ right\\ greater\\ than\\ left\\,\\ in\\ an\\ enlarged\\ thyroid\\ gland\\.\\ \\ the\\ pyramidal\\ lobe\\ is\\ visible\\.\ \(0\)\
\-\ graves\\'\\ disease\ \(0\)\
\-\ graves\\'\\ disease\ \(0\)\
\-\ 17\\-year\\ old\\ white\\ male\\ with\\ three\\ to\\ four\\-month\\ history\\ of\\ proptosis\\,\\ tachycardia\\,\\ heat\\ intolerance\\ and\\ weight\\ loss\\.\\ \\ patient\\ placed\\ on\\ atenolol\\ for\\ control\\ of\\ heart\\ rate\\.\ \(0\)\
\-\ graves\\â\\€\\™\\ disease\\ is\\ the\\ most\\ common\\ cause\\ of\\ thyrotoxicosis\\.\\ \\ the\\ peak\\ incidence\\ is\\ in\\ the\\ third\\ and\\ fourth\\ decades\\ with\\ a\\ female\\ predominance\\ of\\ 5\\:1\\.\\ \\ it\\ is\\ an\\ autoimmune\\ disorder\\ characterized\\ by\\ circulating\\ thyroid\\ stimulating\\ immunoglobulins\\,\\ which\\ bind\\ to\\ the\\ thyroid\\ stimulating\\ receptors\\ of\\ the\\ thyroid\\ cells\\ causing\\ thyroid\\ gland\\ hypertrophy\\ and\\ increased\\ synthesis\\ and\\ secretion\\ of\\ thyroid\\ hormone\\.\\ \\ symptoms\\ include\\ tachycardia\\,\\ heat\\ intolerance\\,\\ weight\\ loss\\,\\ diarrhea\\,\\ agitation\\ or\\ nervousness\\,\\ tremor\\ and\\ weakness\\.\\ \\ this\\ patient\\ was\\ atypical\\ based\\ on\\ the\\ fact\\ that\\ he\\ was\\ a\\ young\\ male\\.\\ \ \(0\)\
\-\ laboratory\\ findings\\ in\\ graves\\â\\€\\™\\ disease\\ include\\ suppressed\\ tsh\\ and\\ elevated\\ levels\\ of\\ free\\ t4\\ and\\ t3\\.\\ \\ the\\ 24\\-hour\\ radioiodine\\ uptake\\ will\\ be\\ increased\\ above\\ 30\\%\\.\\ \\ thyroid\\ scans\\ using\\ tc99m\\ show\\ diffuse\\,\\ homogenous\\ uptake\\ within\\ an\\ enlarged\\ gland\\.\\ \\ \\ this\\ patient\\ had\\ the\\ classic\\ signs\\ and\\ symptoms\\ of\\ hyperthyroidism\\ including\\ a\\ diffuse\\ homogenous\\ uptake\\ greater\\ than\\ 80\\%\\ on\\ his\\ nuclear\\ medicine\\ study\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.4113190665649342\ \(0\)\
\-\ uptake\\:\\ 0\\.2414720216124647\ \(0\)\
\-\ graves\\:\\ 0\\.23082235872565088\ \(0\)\
\-\ radioiodine\\:\\ 0\\.2097019995650638\ \(0\)\
\-\ using\\:\\ 0\\.1721890881974124\ \(0\)\
\-\ gland\\:\\ 0\\.1700670656569673\ \(0\)\
\-\ homogenous\\:\\ 0\\.16665267438743056\ \(0\)\
\-\ stimulating\\:\\ 0\\.1345222568340554\ \(0\)\
\-\ of\\:\\ 0\\.13315169879106267\ \(0\)\
\-\ the\\:\\ 0\\.12532143960034936\ \(0\)\
\-\ mci\\:\\ 0\\.1196413767869879\ \(0\)\
\-\ and\\:\\ 0\\.11896650982852414\ \(0\)\
\-\ heat\\:\\ 0\\.11595899267005756\ \(0\)\
\-\ intolerance\\:\\ 0\\.11541117936282544\ \(0\)\
\-\ t3\\:\\ 0\\.11337014636006379\ \(0\)\
\-\ enlarged\\:\\ 0\\.10703982452466525\ \(0\)\
\-\ tachycardia\\:\\ 0\\.10692186055413365\ \(0\)\
\-\ t4\\:\\ 0\\.10498845473961527\ \(0\)\
\-\ tsh\\:\\ 0\\.10114000267488306\ \(0\)\
\-\ hour\\:\\ 0\\.09925625963219714\ \(0\)\
\-\ diffuse\\:\\ 0\\.09846839919069557\ \(0\)\
\-\ disease\\:\\ 0\\.08787959131486661\ \(0\)\
\-\ normal\\:\\ 0\\.08547804789936364\ \(0\)\
\-\ 7\\Â\\µci\\:\\ 0\\.08370086466164882\ \(0\)\
\-\ free\\:\\ 0\\.08148282808842516\ \(0\)\
\-\ an\\:\\ 0\\.08005646678998435\ \(0\)\
\-\ greater\\:\\ 0\\.07711819502276102\ \(0\)\
\-\ bind\\:\\ 0\\.07529372173085588\ \(0\)\
\-\ receptors\\:\\ 0\\.07529372173085588\ \(0\)\
\-\ 24\\:\\ 0\\.07421309053298353\ \(0\)\
\-\ synthesis\\:\\ 0\\.07362088653345482\ \(0\)\
\-\ weight\\:\\ 0\\.07299665604866704\ \(0\)\
\-\ was\\:\\ 0\\.07296212391955584\ \(0\)\
\-\ atenolol\\:\\ 0\\.07220652452682846\ \(0\)\
\-\ 30\\:\\ 0\\.0714088827331191\ \(0\)\
\-\ circulating\\:\\ 0\\.07098134842879458\ \(0\)\
\-\ immunoglobulins\\:\\ 0\\.07098134842879458\ \(0\)\
\-\ agitation\\:\\ 0\\.06990066652168794\ \(0\)\
\-\ pinhole\\:\\ 0\\.06893396361442876\ \(0\)\
\-\ nervousness\\:\\ 0\\.06893396361442876\ \(0\)\
\-\ patient\\:\\ 0\\.06809251644765073\ \(0\)\
\-\ pyramidal\\:\\ 0\\.06805947446322277\ \(0\)\
\-\ secretion\\:\\ 0\\.06652672124627884\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.06521374360266188\ \(0\)\
\-\ loss\\:\\ 0\\.06377322402810494\ \(0\)\
\-\ tremor\\:\\ 0\\.06354090840526082\ \(0\)\
\-\ on\\:\\ 0\\.0632286594129817\ \(0\)\
\-\ include\\:\\ 0\\.062282017514223256\ \(0\)\
\-\ scan\\:\\ 0\\.06210385705659883\ \(0\)\
\-\ suppressed\\:\\ 0\\.060166963129851724\ \(0\)\
\-\ than\\:\\ 0\\.05933856339682997\ \(0\)\
\-\ decades\\:\\ 0\\.059165038714864664\ \(0\)\
\-\ planar\\:\\ 0\\.05885398548623476\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.05885398548623476\ \(0\)\
\-\ autoimmune\\:\\ 0\\.05855313258271972\ \(0\)\
\-\ predominance\\:\\ 0\\.05797949633502878\ \(0\)\
\-\ tc99m\\:\\ 0\\.05770558968141272\ \(0\)\
\-\ is\\:\\ 0\\.05733315843808716\ \(0\)\
\-\ symptoms\\:\\ 0\\.0572734678209512\ \(0\)\
\-\ ablation\\:\\ 0\\.05718115028883371\ \(0\)\
\-\ increased\\:\\ 0\\.05660448548860758\ \(0\)\
\-\ peak\\:\\ 0\\.05363243417691871\ \(0\)\
\-\ hormone\\:\\ 0\\.053292573416002714\ \(0\)\
\-\ proptosis\\:\\ 0\\.05280528059843754\ \(0\)\
\-\ fact\\:\\ 0\\.05020537621197531\ \(0\)\
\-\ determined\\:\\ 0\\.04985468926514739\ \(0\)\
\-\ diarrhea\\:\\ 0\\.0495169140120244\ \(0\)\
\-\ nuclear\\:\\ 0\\.0495169140120244\ \(0\)\
\-\ nontender\\:\\ 0\\.04929844675061977\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.04929844675061977\ \(0\)\
\-\ characterized\\:\\ 0\\.04808677351226477\ \(0\)\
\-\ fourth\\:\\ 0\\.046932815299575596\ \(0\)\
\-\ male\\:\\ 0\\.046606343540767335\ \(0\)\
\-\ visible\\:\\ 0\\.046134469253380515\ \(0\)\
\-\ medicine\\:\\ 0\\.046134469253380515\ \(0\)\
\-\ scans\\:\\ 0\\.045542315963086104\ \(0\)\
\-\ incidence\\:\\ 0\\.04505378734627388\ \(0\)\
\-\ control\\:\\ 0\\.04472010724675416\ \(0\)\
\-\ disorder\\:\\ 0\\.04427244814738699\ \(0\)\
\-\ young\\:\\ 0\\.04315715589559728\ \(0\)\
\-\ causing\\:\\ 0\\.04299281971448175\ \(0\)\
\-\ atypical\\:\\ 0\\.04293868863419265\ \(0\)\
\-\ be\\:\\ 0\\.0424633801906664\ \(0\)\
\-\ nodules\\:\\ 0\\.041586216855460156\ \(0\)\
\-\ levels\\:\\ 0\\.041493537365466286\ \(0\)\
\-\ 80\\:\\ 0\\.04082676527825865\ \(0\)\
\-\ placed\\:\\ 0\\.040783990415256786\ \(0\)\
\-\ range\\:\\ 0\\.040614857672284836\ \(0\)\
\-\ cells\\:\\ 0\\.040326176149943334\ \(0\)\
\-\ third\\:\\ 0\\.03985149143016524\ \(0\)\
\-\ rate\\:\\ 0\\.03966073213710595\ \(0\)\
\-\ to\\:\\ 0\\.03925366460761907\ \(0\)\
\-\ classic\\:\\ 0\\.039146787074271966\ \(0\)\
\-\ in\\:\\ 0\\.0390604581517175\ \(0\)\
\-\ weakness\\:\\ 0\\.03819795212104496\ \(0\)\
\-\ laboratory\\:\\ 0\\.03800679538407077\ \(0\)\
\-\ based\\:\\ 0\\.03791269003095987\ \(0\)\
\-\ above\\:\\ 0\\.037757961381084316\ \(0\)\
\-\ including\\:\\ 0\\.03745611865163425\ \(0\)\
\-\ palpable\\:\\ 0\\.036769803197480654\ \(0\)\
\-\ signs\\:\\ 0\\.03657893051776553\ \(0\)\
\-\ heart\\:\\ 0\\.03639194780080229\ \(0\)\
\-\ labs\\:\\ 0\\.03626068388108717\ \(0\)\
\-\ this\\:\\ 0\\.0359689921084171\ \(0\)\
\-\ elevated\\:\\ 0\\.03567994150822175\ \(0\)\
\-\ cause\\:\\ 0\\.035655506895922125\ \(0\)\
\-\ 15\\:\\ 0\\.03536725727941053\ \(0\)\
\-\ three\\:\\ 0\\.03513377924903917\ \(0\)\
\-\ study\\:\\ 0\\.034906095320364476\ \(0\)\
\-\ white\\:\\ 0\\.03453154570339971\ \(0\)\
\-\ will\\:\\ 0\\.033686542999090054\ \(0\)\
\-\ show\\:\\ 0\\.033225767111933806\ \(0\)\
\-\ treated\\:\\ 0\\.03259274430419434\ \(0\)\
\-\ neck\\:\\ 0\\.03201698993067976\ \(0\)\
\-\ his\\:\\ 0\\.03174211782312522\ \(0\)\
\-\ for\\:\\ 0\\.031726874573172366\ \(0\)\
\-\ he\\:\\ 0\\.030993018589195686\ \(0\)\
\-\ with\\:\\ 0\\.030745674669083543\ \(0\)\
\-\ shows\\:\\ 0\\.030718248428779696\ \(0\)\
\-\ 10\\:\\ 0\\.030604973020934113\ \(0\)\
\-\ lobe\\:\\ 0\\.030246198021749337\ \(0\)\
\-\ significant\\:\\ 0\\.03021917240133841\ \(0\)\
\-\ common\\:\\ 0\\.029681998528580774\ \(0\)\
\-\ patients\\:\\ 0\\.029443342173794344\ \(0\)\
\-\ physical\\:\\ 0\\.02837920705475365\ \(0\)\
\-\ without\\:\\ 0\\.02760665991708909\ \(0\)\
\-\ most\\:\\ 0\\.027238608311370302\ \(0\)\
\-\ were\\:\\ 0\\.026979051799088254\ \(0\)\
\-\ it\\:\\ 0\\.02679141353180768\ \(0\)\
\-\ exam\\:\\ 0\\.0263472928788769\ \(0\)\
\-\ had\\:\\ 0\\.026077030169620707\ \(0\)\
\-\ findings\\:\\ 0\\.025831213570243768\ \(0\)\
\-\ female\\:\\ 0\\.02525580333477035\ \(0\)\
\-\ within\\:\\ 0\\.024105559369705213\ \(0\)\
\-\ has\\:\\ 0\\.02390676148947853\ \(0\)\
\-\ which\\:\\ 0\\.02379889612966135\ \(0\)\
\-\ that\\:\\ 0\\.02271300294889677\ \(0\)\
\-\ by\\:\\ 0\\.02222601810461865\ \(0\)\
\-\ history\\:\\ 0\\.019996386853339813\ \(0\)\
\-\ or\\:\\ 0\\.018207677663123492\ \(0\)\
\-\ left\\:\\ 0\\.01785384844161864\ \(0\)\
\-\ right\\:\\ 0\\.017352421635688575\ \(0\)\
\-\ old\\:\\ 0\\.015490129551343441\ \(0\)\
